SCHEMBL18016597

SCHEMBL18016597

COC1[C@@H](OC)[C@@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@H]2O[C@@H](n3cnc4c(=O)[nH]c(C)nc43)[C@@H](O)C2OC)O[C@H]1n1c[n+](C)c2c(=O)[nH]c(N)nc21

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TGM2 P21980 1/20 0.56
FUT5 Q11128 1/20 0.54
KRAS P01116 2/20 0.53
NT5E P21589 1/20 0.52
DCPS Q96C86 1/20 0.52
RNASEL Q05823 4/20 0.49
P2RY6 Q15077 2/20 0.49
P2RY2 P41231 1/20 0.49
P2RY4 P51582 1/20 0.49
P2RX3 P56373 2/20 0.48
TAS1R3 Q7RTX0 1/20 0.47
TAS1R1 Q7RTX1 1/20 0.47
P2RY1 P47900 2/20 0.47
P2RY11 Q96G91 2/20 0.47
ENPP1 P22413 1/20 0.47
P2RX1 P51575 1/20 0.47
P2RX4 Q99571 1/20 0.47
IMPDH2 P12268 1/20 0.46
IMPDH1 P20839 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17210951 1.00 TGM2 (0.56) TGM2FUT5KRASNT5EDCPS
SCHEMBL15746468 1.00 TGM2 (0.56) TGM2FUT5KRASNT5EDCPS
SCHEMBL18016594 0.98 TGM2 (0.58) TGM2FUT5KRASNT5EDCPS
SCHEMBL15746448 0.98 TGM2 (0.58) TGM2FUT5KRASNT5EDCPS
SCHEMBL17210952 0.98 TGM2 (0.58) TGM2FUT5KRASNT5EDCPS
SCHEMBL17210947 0.97 TGM2 (0.60) TGM2FUT5KRASNT5EDCPS
SCHEMBL18295132 0.97 TGM2 (0.60) TGM2FUT5KRASNT5EDCPS
SCHEMBL15746457 0.97 TGM2 (0.57) TGM2FUT5KRASNT5EDCPS
SCHEMBL18016588 0.97 TGM2 (0.60) TGM2FUT5KRASNT5EDCPS
SCHEMBL15746466 0.97 TGM2 (0.60) TGM2FUT5KRASNT5EDCPS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180000910-A1 TERMINALLY MODIFIED RNA ARES CAPITAL CORPORATION, AS AGENT 2018-01-04 US disclosed
US-20170175129-A1 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS INC (US) 2017-06-22 US disclosed
US-20160354493-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF MODERNATX, INC. 2016-12-08 US disclosed
US-20160354491-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS INC (US) 2016-12-08 US disclosed
US-20160354490-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS INC (US) 2016-12-08 US disclosed
US-20160348099-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS INC (US) 2016-12-01 US disclosed
US-20160304552-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. 2016-10-20 US disclosed
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2016-09-15 US disclosed
US-20160237108-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF ARES CAPITAL CORPORATION, AS AGENT 2016-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF POLRMT, POLN, NSUN3 TGM2 2867/4885FUT5 1345/4885KRAS 2506/4885
US-20160304552-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, ADAR, NSUN3 TGM2 1916/4885FUT5 1042/4885KRAS 1439/4885
US-20180000910-A1 TERMINALLY MODIFIED RNA RNGTT, NSUN3, RNMT TGM2 3781/4885FUT5 641/4885KRAS 2697/4885
US-20160348099-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, ADAR, NSUN3 TGM2 1916/4885FUT5 1042/4885KRAS 1439/4885
US-20160354490-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, ADAR, NSUN3 TGM2 1916/4885FUT5 1042/4885KRAS 1439/4885
US-20160354491-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, ADAR, NSUN3 TGM2 1916/4885FUT5 1042/4885KRAS 1439/4885
US-20170175129-A1 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, RNGTT, NSUN3 TGM2 2234/4885FUT5 2056/4885KRAS 1591/4885
US-20160354493-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, ADAR, NSUN3 TGM2 1916/4885FUT5 1042/4885KRAS 1439/4885
US-20160237108-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF NSUN3, POLRMT, TRDMT1 TGM2 2945/4885FUT5 261/4885KRAS 1685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.